You may not experience any of them.Note: Arcoxia has not been approved by the FDA for the U.S. market.Keep your tablets in the blister pack until it is time to take them. Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. Adis is an information provider. We comply with the HONcode standard for trustworthy health information - Therefore, the daily doses stated above for each condition should not be exceeded.If you have mild liver disease, you should not take more than 60 mg a day. Sometimes they are serious, most of the time they are not. This non-approvable letter was due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) and questions on the benefit-risk ratio in patients taking Arcoxia. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Gavreto (pralsetinib) is an oral selective RET kinase inhibitor for the...Onureg (azacitidine) is a nucleoside metabolic inhibitor indicated for the...Qdolo (tramadol hydrochloride) is an opioid agonist indicated in adults for ...Xaracoll (bupivacaine hydrochloride) is a fully bioresorbable collagen implant...The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. The Concomitant use of drugs that are strong inducers of the Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein It was approved for use in Europe in August 2014, in the US in July 2015, and in India in December 2015; it was first in the class of NS5A inhibitors to reach the market.In December 2014 BMS announced that it would offer the drug for sale at different prices in different countries, depending on the level of economic development, and that it would license the drug to generics manufacturers for sale in the developing world.As of January 2016 a twelve-week course cost around $63,000 in the US, around $39,000 in the UK, around $37,000 in France, and $525 in Egypt, and by that time BMS had joined the Daclatasvir has been tested in combination regimens with CC(C)[C@@H](C(=O)N1CCC[C@H]1c2[nH]c(cn2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OCInChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1 Heat and dampness can destroy some medicines.Keep it where children cannot reach it. Following the lapse / withdrawal of the marketing authorization in each country, the patents in that country will also be allowed to lapse. Arcoxia reduces pain and inflammation by blocking COX-2, an enzyme in the body. Some people developed ulcers whether they were taking Arcoxia or placebo in these studies; however the rate was higher on Arcoxia.If any of the following symptoms: shortness of breath, chest pains or ankle swelling appear or worsen, stop your treatment with Arcoxia and consult a doctor, as soon as is practical.If you have kidney, liver or heart disease, your doctor will want to appropriately keep a check on you.If you develop any symptoms that could indicate a severe allergic reaction such as an inability to breathe or a serious skin reaction you must consult a doctor on an urgent basis.Your doctor will want to discuss your treatment from time to time. Select one or more newsletters to continue. Posology. The FDA issued a complete response letter for NS5A inhibitor daclatasvir saying it was unable to approve the drug because the marketing application was for its use in tandem with asunaprevir, an NS3/NS4A protease inhibitor discontinued in the US by BMS last month for commercial reasons.